anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Supervised Group-based intervention involves no professional walking fitness coach; however, the research team member will ask the participants to engage in the intervention in a form of group, and complete the intervention according to goals and targets of each session. The intervention groups will receive an 18-week walking training (3 sessions per week, 1 hour per session )in accordance with the intervention.
The invention relates to a method for automatically adjusting an image data set, a data memory and an X-ray device. The invention relates to a method (1) for automatically adjusting an image data set acquired by means of an X-ray device, a computer program, a data memory and an X-ray device. In the method, a binary mask is generated for a single image (2) of an image data set, which binary mask distinguishes different components (4, 5) of an imaged target object (3) from one another. A reference image of the image data set is thus determined, the reference image containing a maximum continuous region (4) of a component. The offset is determined on the basis of the mean value determined for the region (4) and a predefined target value, such that the pixel values used for determining the mean value are adjusted by applying the offset to the pixel values, such that the mean value of the pixel values adjusted by means of the offset corresponds to the predefined target value. The determined offset is then applied to all pixel values of the image data set.
INTRODUCTION: Spasticity is common after a stroke and is an independent risk factor for developing pain. BotulinumtoxinA injection is the treatment of choice for focal spasticity. We examined the effect of intramuscular botulinumtoxinA on pain relief in patients in routine clinical practice who were experiencing pain as a primary complaint associated with post-stroke lower limb spasticity.
METHODS: Prospective, multicentre, post-marketing observational study. The study period was 16 months. The primary effectiveness variable was the mean change from baseline on the pain 0-10 Numerical Rating Scale after four botulinumtoxinA injection cycles. Secondary endpoints included changes from baseline on the pain 0-100 Visual Analogue Scale, Goal Attainment Scale, modified Ashworth Scale, 10-Meter Walk Test, Penn Spasm Frequency Scale, and 36-item Short-Form Health Survey.
RESULTS: Of 186 enrolled patients, 180 (96.8%) received botulinumtoxinA at least once. The mean (standard deviation) pain 0-10 Numerical Rating Scale score decreased significantly (p<0.0001) from 4.9 (2.2) at baseline to 2.5 (2.1) at study end, representing a 50% decrease in pain severity. Relief of pain due to spasticity was supported by improvement from baseline in all secondary variables except the 10-Meter Walk Test. Two adverse events (erysipelas and phlebitis) in one patient were considered likely to be related to botulinumtoxinA injection.
CONCLUSION: BotulinumtoxinA appears to provide pain relief as an additional benefit of local treatment in patients with post-stroke lower limb spasticity for whom pain relief is a primary therapeutic goal (a Lay Abstract has been provided as Appendix A).
The invention relates to a blood-pressure-lowering health-care oral liquid and a preparation method thereof. The oral liquid is composed of the raw materials of, by weight: 15-20 parts of apple juice, 10-20 parts of citric acid, 2-3 parts of corn, 4-6 parts of glutinous rice, 2-4 parts of edible amaranth, 1-2 parts of lobed kudzuvine root, 3-4 parts of greenish lily bulb, 2-3 parts of periploca forrestii, 3-4 parts of water dropwort, 2-3 parts of florists dendranthema, 2-3 parts of Chinese chive, 1-2 parts of pseudostellaria hetero phyllaphylla, 1-2 parts of eucommia leaf, 2-3 parts of tree peony root-bark, 1-2 parts of lucid ganoderma, and 1-2 parts of epimedium. The oral liquid provided by the invention has the advantages of high health-care value, fast absorption, good taste, and no odor such as bitterness. The oral liquid can be directly drunk without adding water. Lobed kudzuvine root has a blood-pressure-lowering effect, and epimedium, eucommia leaf, tree peony root-bark, and lucid ganoderma have the blood-pressure-lowering effect. The oral liquid is suitable for patients with high blood pressure, and assists in blood-pressure-lowering health care.
PURPOSE: To evaluate how often tests of structure and function detect glaucoma progression at the same study visit. Tests include current glaucoma clinical tests and a new 3-dimensional (3D) optical coherence tomography (OCT) rim measurement.
DESIGN: Prospective cohort study.
METHODS: For 124 open-angle glaucoma patients at a single institution, one eye was randomly selected for each patient. Patients were included if they had open-angle glaucoma and if they had at least 4 yearly study visits. Study visits included a full dilated eye exam, disc photography (DP), Humphrey visual field (HVF 24-2) testing, 2D OCT retinal nerve fibre layer (RNFL) thickness measurements, and 3D OCT neuroretinal rim measurements (i.e., minimum distance band or MDB). For each test at each study visit, eyes were classified as progressors or non-progressors using event-based analysis. Agreement occurred if tests progressed in the same eye at the same study visit. Agreements between all compared tests were calculated as percentages of agreement.
RESULTS: The study included 124 open-angle glaucoma eyes, which had an average follow-up period of 66.9 ± 16.4 months. Structural tests (i.e., DP, global RNFL thickness, and global MDB rim thickness) progressed at the same visit as the functional test (i.e., HVF testing) in only 5.0% (3/60) to 16.0% (13/81) of eyes. Global MDB thickness and global RNFL thickness showed similar agreement with functional HVF testing (i.e., 16.0% [13/81] and 8.3% [7/84], respectively), and global MDB thickness showed better structure-function agreement with HVF testing than between DP and HVF testing (i.e., 5.0% [3/60], P = 0.04). For all paired comparisons between testing methods, eyes with moderate glaucoma showed similar or better agreement than eyes with mild or severe glaucoma.
CONCLUSIONS: Clinical tests of structure and function do not usually progress at the same clinic visit. Most of the time, glaucoma progression is only detected by one or two tests.
BACKGROUND: Early recognition of haemodynamic instability after birth and prompt interventions are necessary to reduce adverse maternal outcomes due to postpartum haemorrhage. Obstetric shock Index (OSI) has been recommended as a simple, accurate, reliable, and low-cost early diagnostic measure that identifies hemodynamically unstable women.
OBJECTIVES: We determined the prevalence of abnormal obstetric shock index and associated factors among women in the immediate postpartum period following vaginal delivery at Mbarara Regional Referral Hospital (MRRH) in southwestern Uganda.
METHODS: We conducted a cross-sectional study at the labour suite and postnatal ward of MRRH from January 2022 to April 2022. We systematically sampled women who had delivered vaginally, and measured their blood pressures and pulse rates at 1 h postpartum. We excluded mothers with hypertensive disorders of pregnancy. Sociodemographic, medical and obstetric data were obtained through interviewer-administered questionnaires. The prevalence of abnormal OSI was the proportion of participants with an OSI ≥ 0.9 (calculated as the pulse rate divided by the systolic BP). Logistic regression analysis was used to determine associations between abnormal OSI and independent variables.
RESULTS: We enrolled 427 women with a mean age of 25.66 ± 5.30 years. Of these, 83 (19.44%), 95% CI (15.79-23.52) had an abnormal obstetric shock index. Being referred [aPR 1.94, 95% CI (1.31-2.88), p = 0.001], having had antepartum haemorrhage [aPR 2.63, 95% CI (1.26-5.73), p = 0.010] and having a visually estimated blood loss > 200 mls [aPR 1.59, 95% CI (1.08-2.33), p = 0.018] were significantly associated with abnormal OSI.
CONCLUSION: Approximately one in every five women who delivered vaginally at MRRH during the study period had an abnormal OSI. We recommend that clinicians have a high index of suspicion for haemodynamic instability among women in the immediate postpartum period. Mothers who are referred in from other facilities, those that get antepartum haemorrhage and those with estimated blood loss > 200mls should be prioritized for close monitoring. It should be noted that the study was not powered to study the factors associated with AOSI and therefore the analysis for factors associated should be considered exploratory.
BACKGROUND: White Sponge Nevus (WSN) is traditionally considered a benign genetic disorder affecting the oral mucosa, primarily caused by pathogenic mutations in keratin 4 (KRT4) or keratin 13 (KRT13). Despite its benign nature, recent evidence has begun to question the malignant potential of WSN.
CASE PRESENTATION: We report a case involving a 70-year-old man who presented with a white lesion on the right floor of his mouth. Initial diagnostic evaluations confirmed the lesion as WSN. Over a one-year follow-up, the lesion underwent malignant transformation, evolving into local epithelial moderate-to-severe dysplasia. Exome sequencing identified a novel insertion mutation in exon 1 of the KRT4 gene, resulting in a deletion-insertion amino acid mutation involving glycine. Single-cell RNA sequencing further revealed altered epithelial proliferation and differentiation dynamics within the lesion.
CONCLUSIONS: This case not only expands the known genetic spectrum of KRT4 mutations associated with WSN but also provides preliminary evidence suggesting the malignant potential of WSN. The novel pathogenic mutation in KRT4 is postulated to alter epithelial proliferation and differentiation, thereby raising concerns about the malignant transformation of WSN. Further studies are warranted to confirm these findings.
2116684 9305780 PCTABS00021 An anti-hypotensive formulation comprising an essentially arginine-free or low arginine (less than about 0.1 %, most preferably, about 0.01 %) containing mixture of amino acids is provided. The formulations may further include ornithine, citrulline or both.  Combination regimens of the described TPN solutions and an arginine analog, or the TPN formations with an anti-endotoxine antibody, an interleukin-1 receptor antagonist, or an anti-tumor necrosis antibody are also provided. Methods for prophylaxis and treatment of systemic hypotension in employing these combination regimens are also provided. A method for treating hypotension caused by nitric oxide synthesis, through administering a low or essentially arginine-free parenteral formulation is described. Methods for treating an animal in septic shock are also disclosed. Prophylaxis or treatment of systemic hypotension, particularly that hypotension incident to chemotherapeutic treatment with biologic response modifiers, such as tumor necrosis factor or interleukin-1 or -2, may be accomplished through the administration of the defined anti-hypotensive formulations or combination regimens with a TPN  formulation until physiologically acceptable systolic blood pressure levels are achieved in the animal. Treatment of an animal for septic shock induced by endotoxin may also be accomplished by administering to the animal the arginine-free formulations described.  Methods for providing nutritional support for an animal at risk of or in septic shock may also be provided through the administration of an arginine-free formulation or the combination regimens.
Cesarean section is one of the most common surgeries performed today with over one million performed in the United States annually. Enhanced Recovery After Surgery (ERAS) is a standardized set of guidelines which has been utilized in multiple surgical disciplines, including colorectal, urologic, gynecologic, and hepatobiliary surgery. ERAS guidelines are now being adopted for the obstetric population and provide evidence-based guidelines for perioperative care for cesarean delivery. Part of the preoperative ERAS pathway includes the recommendation for oral administration of a carbohydrate- containing fluid prior to surgery. A Cochrane review found that across several trials, carbohydrate loading was associated with favorable outcomes such as decreased time to passage of gas and reduction in length of hospital stay. Maternal outcomes are improved due to the decrease in insulin resistance that perioperative carbohydrate loading provides. During surgery, the body enters a catabolic state leading to insulin resistance that may delay recovery. Preoperative carbohydrate drinks have also been given to patients with diabetes, and although the decrease in insulin resistance is less certain, there seems to be less risk of postoperative hyperglycemia and the practice is considered safe but needing more study.

While it is clear that ERAS provides benefits to the mother, less is understood about the effects on the fetus and neonate. Fetal and neonatal glucose level is known to be strongly tied to the level of insulin resistance and glucose level in the mother, particularly in the immediate time period prior to birth. Neonatal hypoglycemia after delivery is an important determinate of health, as hypoglycemia has been linked to poor neurologic outcomes. Cesarean section is a known risk factor for neonatal hypoglycemia requiring IV dextrose with an odds ratio of 1.4. There are known risk factors for neonatal hypoglycemia, such as being the infant of a diabetic mother, preterm, weight \<2500g, or \>4500g, and poor feeding, however, the incidence of hypoglycemia in neonates with no clear risk factors is 5-15%. With health care systems adopting the ERAS protocol as part of the standardized guidelines for perioperative care, it will be important to understand the effect of carbohydrate loading on both maternal and neonatal glucose levels as well as other outcomes.
The present invention provides a vector which can make nucleic acids to be an aggregate and locate a vector containing a cationic polymer to surround the aggregate so as to protect the nucleic acids from the enzyme. The vector comprises a polymer having branched chain(s). Preferably, 3, 4, or 6 branched chains are bonded to benzene ring. It is preferable that the number of the branched chains is higher. As the branched chain(s), a vinyl-series acrylic polymer is preferable. The vector is synthesized by reacting a dithiocarbamate compound with an acrylamide monomer for the branched chain(s).
One aspect of the present invention relates to a nucleic acid construct which includes a first nucleic acid and a second nucleic acid operatively coupled to the first nucleic acid. The first nucleic acid molecule encodes a first peptide that has the sequence of InvX or another sequence incorporating the 58 amino acid cellular import region of Mce1A and confers on  Mycobacterium tuberculosis  an ability to enter mammalian cells. The second nucleic acid molecule encoding a second peptide. Expression of the nucleic acid construct produces a fusion protein comprising the first peptide coupled to the second peptide. The second peptide may be a therapeutic or a diagnostic peptide. An alternative embodiment of the nucleic acid construct includes the first nucleic acid and an insertion site suitable for incorporation of the second nucleic acid molecule into this version of the construct. The present invention further relates to the fusion protein per se, screening methods for identifying fusion proteins having a protective effect against a pathogen, and therapeutic fusion proteins.
BACKGROUND: The Bethesda system classifies all fine-needle aspiration specimens into 1 of 6 categories. We speculated that cancers within each Bethesda category would have distinct clinical behavior.
METHODS: This is a retrospective analysis of patients from a single academic medical center with a histologic diagnosis of thyroid cancer who had an initial diagnosis of Bethesda III, IV, V, or VI cytology.
RESULTS: A total of 556 cases were included, with 87 cases of Bethesda III, 109 cases of IV, 120 cases of V, and 240 cases of VI. Bethesda III showed similarities with V/VI compared to IV with a predominance of papillary thyroid cancer. The interval from diagnosis to surgery was longer in Bethesda III compared to Bethesda V/VI (median 78 vs 41 days, P < .001) (Fig. 1). Yet, patients with Bethesda III had a higher probability of achieving remission (62% vs 46%, P < .03), a lower possibility of recurrence (8% vs 24%, P < .001), and a shorter interval to achieve remission (median 1218 vs 1682 days, P = .02) compared to Bethesda V/VI, which did not change after adjusting for age, sex, radioactive iodine therapy, mode of surgery, and tumor size. More than 70% of Bethesda III that later presented with recurrence had T3/T4 disease or distant metastasis.
CONCLUSION: Cancers with Bethesda III cytology had a less aggressive clinical phenotype with better prognosis compared to V/VI despite histological similarities. The time to remission was shorter in Bethesda III despite a longer interval between diagnosis and surgery. The initial cytological diagnosis may guide management.
155,272. Adler, R. Dec. 5, 1919, [Convention date]. Drainage appliances.-Adsorptive appliances in the form of disks, cones, or sticks for use in the treatment of wounds are prepared by mixing finely-divided adsorption charcoal with plastio clay or precipitated silicic acid and water, shaping to the desired form, and drying at a temperature which will not destroy the colloid character of the clay &c. In an example a mixture of 30 parts charcoal, 70 parts clay, and 70 parts water is shaped into cones and dried at 70‹ C. Antiseptics may be added to the mixture before shaping. The Specification as open to inspection under Sect. 91 (3) (a) refers also to the use of jelly-like silicates and gypsum as binding agents for the charcoal and to the use of tablets &c. containing a smaller proportion of the binding agent as medicines for internal administration. The prior use of tablets &c. of adsorptive charcoal mixed with binding agents such as gelatinous substances, gums, resins, starch, dextrin, and the like is also referred to. This subject-matter does not appear in the Specification as accepted.
Current standard treatment for WG involves various medications and is based on disease severity. Unfortunately, more than 50% of people experience a relapse after remission, placing them at risk for additional organ damage and medication toxicity. To prevent this, safer and more effective treatments for mild relapses are needed. Several studies have shown that activated T cells, a type of white blood cell important in regulating immune responses, play a role in WG. Abatacept, an immunoglobulin-based medication approved by the FDA to treat rheumatoid arthritis, acts by preventing T-cell activation and may be useful in treating mild relapses of WG. The purpose of this study is to determine the safety and effectiveness of abatacept in treating adults with mild relapsing WG.

Participants will receive abatacept intravenously at study visits on Days 1, 15, and 29, and then once a month thereafter. A participant's abatacept dose is based on body weight and will remain the same throughout the study. Participants who are receiving maintenance immunosuppressive medications consisting of methotrexate, azathioprine, or mycophenolate mofetil at the time of enrollment will remain on these medications without dosage increase or reduction. Eligible participants may be on up to prednisone 15mg daily at the time of relapse. Following the development of relapse, participants may be treated with up to prednisone 30mg daily if necessary, but must to be back to the same dose that they had been on prior to relapse by Month 2. All study visits include medication review, physical exam, blood and urine collection, and questionnaires. A chest x-ray, computed tomography (CT) scan of the chest and sinuses, and lung function testing will occur at some study visits. Participants whose symptoms did not improved by Month 2 will be taken off abatacept. Any participants undergoing early termination or, after common closing, will undergo three follow-up study visits at 1, 3, and 6 months after the end of treatment.
Participants will receive DI-Leu16-IL2 2.0 mg/m\^2 SC for 3 consecutive days every 3 weeks (21-day cycle). Participants will continue to receive therapy through the duration of the study as long as they will have clinical benefit and will not experience any untoward side effects.
The invention belongs to the technical field of medicines, relates to a nimodipine solid dispersion and a preparation method thereof, and particularly relates to a nimodipine solid dispersion taking HPMC and povidone composition as carriers, and preparation and application thereof. The invention adopts nimodipine as an active ingredient, and povidone and HPMC as a crystal inhibitor are added by a solvent volatilization method to prepare the solid dispersion. The solid dispersion particles are prepared by utilizing a fluidized bed technology, and then the nimodipine tablets are prepared. The ratio of the nimodipine to the povidone to the HPMC is 1: 1-6: 0.2-5. Compared with the bulk drug, the prepared solid dispersion preparation has obviously increased in-vitro dissolution rate and similar dissolution behavior with the original Yannnite film under a distinguishing medium. The invention applies HPMC as a crystallization inhibitor to the preparation of solid dispersion and tablets of nimodipine with PVP as a carrier, improves the phenomenon that the solid dispersion is crystallized after being rapidly released in water, inhibits the crystallization behavior of the solid dispersion in water and enables the solid dispersion to be slowly released in water.
In an aspect an apparatus for determining toxic load quantifiers is presented. An apparatus includes at least a processor and a memory communicatively connected to the at least a processor. A memory contains instructions configuring at least a processor to receive user input comprising user data. At least a processor is configured to generate a query as a function of user data. At least a processor is configured to obtain query results as a function of a query. At least a processor is configured to determine a toxic load quantifier of a query results of query results as a function of a toxicity criterion and user data. At least a processor is configured to display a toxic load quantifier of query results to a user.